IRIS Accounts Production v25.3.0.601 14583567 Board of Directors 1.2.24 31.1.25 31.1.25 28.10.2025 false true false false true false Auditors Opinion Ordinary 0.01000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh145835672024-01-31145835672025-01-31145835672024-02-012025-01-31145835672023-01-09145835672023-01-102024-01-31145835672024-01-3114583567ns15:EnglandWales2024-02-012025-01-3114583567ns14:PoundSterling2024-02-012025-01-3114583567ns10:Director12024-02-012025-01-3114583567ns10:PrivateLimitedCompanyLtd2024-02-012025-01-3114583567ns10:SmallEntities2024-02-012025-01-3114583567ns10:Audited2024-02-012025-01-3114583567ns10:SmallCompaniesRegimeForDirectorsReport2024-02-012025-01-3114583567ns10:SmallCompaniesRegimeForAccounts2024-02-012025-01-3114583567ns10:FullAccounts2024-02-012025-01-3114583567ns10:OrdinaryShareClass12024-02-012025-01-3114583567ns10:Director22024-02-012025-01-3114583567ns10:Director32024-02-012025-01-3114583567ns10:RegisteredOffice2024-02-012025-01-3114583567ns5:CurrentFinancialInstruments2025-01-3114583567ns5:CurrentFinancialInstruments2024-01-3114583567ns5:RetainedEarningsAccumulatedLosses2025-01-3114583567ns5:RetainedEarningsAccumulatedLosses2024-01-3114583567ns5:WithinOneYearns5:CurrentFinancialInstruments2025-01-3114583567ns5:WithinOneYearns5:CurrentFinancialInstruments2024-01-3114583567ns10:OrdinaryShareClass12025-01-31
REGISTERED NUMBER: 14583567 (England and Wales)


















AUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JANUARY 2025

FOR

INAGENE DIAGNOSTICS UK LTD.

INAGENE DIAGNOSTICS UK LTD. (REGISTERED NUMBER: 14583567)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


INAGENE DIAGNOSTICS UK LTD.

COMPANY INFORMATION
FOR THE YEAR ENDED 31 JANUARY 2025







DIRECTORS: A M Greenberg
H McCarten
G Soesman



REGISTERED OFFICE: 5th Floor
10 Finsbury Square
London
EC2A 1AF



REGISTERED NUMBER: 14583567 (England and Wales)



SENIOR STATUTORY AUDITOR: Shahid Hameed FCA FCCA



AUDITORS: THP Limited
Chartered Accountants
and Statutory Auditors
34-40 High Street
Wanstead
London
E11 2RJ

INAGENE DIAGNOSTICS UK LTD. (REGISTERED NUMBER: 14583567)

BALANCE SHEET
31 JANUARY 2025

2025 2024
Notes £    £   
CURRENT ASSETS
Debtors 4 4,200 25,167
Cash at bank 3,561 5,933
7,761 31,100
CREDITORS
Amounts falling due within one year 5 446,315 313,862
NET CURRENT LIABILITIES (438,554 ) (282,762 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(438,554

)

(282,762

)

RESERVES
Retained earnings (438,554 ) (282,762 )
SHAREHOLDERS' FUNDS (438,554 ) (282,762 )

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 28 October 2025 and were signed on its behalf by:





H McCarten - Director


INAGENE DIAGNOSTICS UK LTD. (REGISTERED NUMBER: 14583567)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025


1. STATUTORY INFORMATION

Inagene Diagnostics UK Ltd. is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern
The accounts have been prepared on a going concern basis despite the deficit in shareholders' funds. The Company is financially supported by its parent company.

The parent company continues to give financial support to the company by injecting funds as necessary and has confirmed it will continue this support for at least 12 months from the date of approving these accounts.

Revenue recognition
Revenue is measured at the fair value of the consideration received or receivable and represents the amount receivable for goods delivered and services provided, net of returns, discounts and value added taxes.

Revenue is recognised when goods are delivered and services are provided to the customer, such that the risks and rewards of ownership have passed to them.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2024 - 1 ) .

INAGENE DIAGNOSTICS UK LTD. (REGISTERED NUMBER: 14583567)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JANUARY 2025


4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade debtors 4,200 -
VAT - 13,577
Prepayments - 11,590
4,200 25,167

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade creditors - 13,964
Amounts owed to group undertakings 428,897 289,441
VAT 218 -
Other creditors - 257
Accrued expenses 17,200 10,200
446,315 313,862

6. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2025 2024
value: £    £   
1 Ordinary 0.01 - -

7. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Shahid Hameed FCA FCCA (Senior Statutory Auditor)
for and on behalf of THP Limited

8. RELATED PARTY DISCLOSURES

Included in creditors is an amount due to the parent company of £428,897 (2024: £289,441). This loan is interest free and repayable on demand.

9. ULTIMATE CONTROLLING PARTY

The immediate parent company is Inagene Diagnostics Inc. (incorporated in Canada and registered office at 2345 Yonge Street, Suite 802, Toronto, Ontario M4P 2E5). The ultimate parent company is Minett Capital Inc., who are also incorporated in Canada and registered at the same address.

The ultimate controlling party is A M Greenberg.